Pattern Bioscience, an Austin, TX-based company which specializes in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, raised $28.7M in Series C funding.
The round, which brought the total amount to $68M, was led by Illumina Ventures and Omnimed Capital and includes participation from the Antimicrobial Resistance Action Fund and Daleshaw.
The company intends to use the funds to complete the development of its rapid phenotypic test platform for infectious diseases, perform clinical validation studies, and submit the platform and its initial pneumonia test for regulatory review with the U.S. Food and Drug Administration (FDA).
Led by CEO Nick Arab, Pattern Bioscience leverages single-cell microbiology technology and a culture-free rapid phenotypic testing platform to deliver clinically actionable results in a timescale that will enable healthcare teams to get treatments to patients fast enough to make the difference. The company’s first tests will target critically ill patients with pneumonia and bacteremia, identifying both the causative pathogen and its antibiotic susceptibility profile in hours, versus days required for traditional culture testing.
FinSMEs
27/04/2023